| A532 |
Tenatumomab Biosimilar(Anti-Tenascin C Reference Antibody)
Featured
|
Tenatumomab (ST2146) is a murine monoclonal antibody against tenascin-C. And tenascin-C, the large extracellular glycoprotein, is overexpressed in cancer. Tenatumomab has been used for Pretargeted Antibody Guided Radioimmunoresearch (PAGRIT), and delivering radionuclides to tumors via PAGRIT and direct 131Iodine labeling approach. |
|
| A533 |
Marstacimab Biosimilar(Anti-TFPI Reference Antibody)
Featured
|
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia. |
|
| A534 |
Befovacimab Biosimilar(Anti-TFPI Reference Antibody)
Featured
|
Befovacimab (BAY 1093884) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitor (TFPI). Befovacimab can be used for haemophilia A/B research. |
|
| A535 |
Jr-141 Biosimilar(Anti-TfR Reference Antibody)
Featured
|
Pabinafusp alfa (JR-141) is a transferrin receptor-targeting antibody consisting of Iduronate 2-sulfatase (HY-P76399) and an anti-human transferrin receptor antibody. Pabinafusp alfa is blood-brain permeable and prevents heparan sulfate (HS) deposition in the central nervous system of mucopolysaccharidosis II (MPS II) mice. Pabinafusp alfa improves learning and prevents central nervous system neuronal damage in mice. |
|
| A536 |
SRK181 Biosimilar（Anti-TGFb1 Reference Antibody）
Featured
|
|
|
| A537 |
Fresolimumab Biosimilar（Anti-TGFb1 Reference Antibody）
Featured
|
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab radiolabeled with 89Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease. |
|
| A538 |
M7824 Biosimilar（Anti-TGFb1 Reference Antibody）
Featured
|
Bintrafusp alfa (M 7824) is a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII fused to a human IgG1 mAb blocking programmed cell death ligand. Bintrafusp alfa can be used for the research of cancer. |
|
| A539 |
Nisevokitug Biosimilar（Anti-TGFb1 Reference Antibody）
Featured
|
Nisevokitug (NIS-793) is a human, IgG2λ antibody targeting TGF-β (TGFB1/TGFB2). Nisevokitug is expressed by CHO-K1 cells. |
|
| A540 |
Genzyme patent anti-TGF-β Biosimilar（Anti-TGFb1 Reference Antibody）
Featured
|
|
|
| A541 |
Zampilimab Biosimilar（Anti-TGM2 / Transglutaminase 2 Reference Antibody）
Featured
|
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant. |
|
| A542 |
Regeneron patent anti-TIE-2 Biosimilar（Anti-TIE2 / CD202b Reference Antibody）
Featured
|
|
|
| A543 |
Tiragolumab Biosimilar（Anti-TIGIT Reference Antibody）
Featured
|
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC). |
|
| A544 |
Vibostolimab Biosimilar（Anti-TIGIT Reference Antibody）
Featured
|
Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research. |
|
| A545 |
Ociperlimab Biosimilar（Anti-TIGIT Reference Antibody）
Featured
|
Ociperlimab is a humanized IgG1 anti-TIGIT antibody. Ociperlimab binds to the extracellular domain of human TIGIT with high affinity (KD = 0.135 nM). Ociperlimab blocks the interaction between TIGIT and its ligands PVR or PVR-L2. Ociperlimab can be used in research of cancer. |
|
| A546 |
Etigilimab Biosimilar（Anti-TIGIT Reference Antibody）
Featured
|
Etigilimab (OMP-313M32), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (CD155; poliovirus receptor) and inhibits downstream signalling with target cell killing. |
|
| A547 |
Domvanalimab Biosimilar（Anti-TIGIT Reference Antibody）
Featured
|
Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used in research of cancer. |
|
| A548 |
Cobolimab Biosimilar(Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody)
Featured
|
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC). |
|
| A549 |
Sabatolimab Biosimilar（Anti-TIM-3 / HAVCR2 / CD366 Reference Antibody）
Featured
|
Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. |
|
| A550 |
Tomaralimab Biosimilar（Anti-TLR2 / CD282 Reference Antibody）
Featured
|
Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS). |
|
| A551 |
CNTO5429 Biosimilar（Anti-TLR3 / CD283 Reference Antibody）
Featured
|
|
|
| A552 |
U.Tokyo patent anti-TLR7 Biosimilar（Anti-TLR7 Reference Antibody）
Featured
|
|
|
| A553 |
Beth Israel Patent Anti-TM4SF1 Biosimilar（Anti-TM4SF1 Reference Antibody）
Featured
|
|
|
| A554 |
Bluefin patent anti-TMEFF1 Biosimilar（Anti-TMEFF1 / Tomoregulin-1 Reference Antibody）
Featured
|
|
|
| A555 |
Janssen patent anti-TMEFF2 Biosimilar（Anti-TMEFF2 Reference Antibody）
Featured
|
|
|
| A556 |
Regeneron patent anti-TMPRSS2 Biosimilar（Anti-TMPRSS2 Reference Antibody）
Featured
|
|
|
| A557 |
Mapatumumab Biosimilar（Anti-TNFRSF10A / TRAILR1 / CD261 Reference Antibody）
Featured
|
Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1). Mapatumumab can be used for the research of cancer. |
|
| A558 |
Lexatumumab Biosimilar（Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody）
Featured
|
Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research. |
|
| A559 |
Drozitumab Biosimilar(Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody)
Featured
|
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma. |
|
| A560 |
Benufutamab Biosimilar(Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody)
Featured
|
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects. |
|
| A561 |
Conatumumab Biosimilar(Anti-TNFRSF10B / TRAILR2 / CD262 Reference Antibody)
Featured
|
Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. . |
|
